Targeting CCL2/CCR2 signaling overcomes MEK inhibitor resistance in Acute Myeloid Leukemia.

Rucha V Modak Katia Graziella de Oliveira Rebola John McClatchy Mona Mohammadhosseini Alisa Damnernsawad Stephen E Kurtz Christopher A Eide Guanming Wu Ted Laderas Tamilla Nechiporuk Marina A Gritsenko Joshua R Hansen Chelsea Hutchinson Sara J C Gosline Paul D Piehowski Daniel Bottomly Nicholas James Short Karin D Rodland Shannon K McWeeney Jeffrey W Tyner Anupriya Agarwal

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Our study demonstrates a compelling rationale for translating CCL2/CCR2 axis inhibitors in combination with MEK pathway-targeting therapies, as a potent strategy for combating drug resistance in AML. This approach has the potential to enhance the efficacy of treatments to improve AML patient outcomes.

Keyphrases

acute myeloid leukemia
cancer therapy
dendritic cells
liver fibrosis
liver injury
regulatory t cells
allogeneic hematopoietic stem cell transplantation
clinical trial
drug induced
risk assessment
immune response
signaling pathway